Back

CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel - a real-world study

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Short and long-term antiplatelet therapy in clinical practice Pharmacogenetics ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Markus Samuel Ritvos

Helsinki University Hospital, Helsinki (Finland)

7 More presentations in this session

Presentation thumbnail
Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome
Doctor D. Cao (Milan, IT)
Abstract Slides
Presentation thumbnail
Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro
Professor B. Curry (Memphis, US)
Abstract Slides
Presentation thumbnail
Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Doctor M. Centore (Salerno, IT)
Abstract Slides
Presentation thumbnail
Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis
Doctor R. Turgeon (Vancouver, CA)
Abstract Slides
Presentation thumbnail
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
Doctor A. Apostolos (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Short and long-term antiplatelet therapy in clinical practice

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists
thumbnail
Congress Session
Pharmacogenetics: a tool to guide clinical decisions
thumbnail
Congress Presentation
CYP2C19 genetic variants and coronary atherosclerosis: insights beyond antiplatelet therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources